The DIRECT consortium proposes to identify biomarkers and define subtypes with rapid diabetes development and progression as well as altered response to diabetes treatment. Furthermore, we will identify, develop and use surrogate response biomarkers that reflect the underlying disease progression in clinical trials.
The DIRECT consortium addresses two fundamental areas of heterogeneity of diabetes:
•The rate at which people´s glycaemia deteriorates either from pre-diabetes to diabetes, or through diabetes with increasing treatment requirements
•The extent to which certain therapeutic interventions (either drug or surgical) results in improvement in glycaemia.
This 7-year project is divided into two phases, a discovery phase and a validation and clinical trial phase. The discovery phase will be undertaken largely in the first 3 years, with validation and clinical trials in years 4 to 7.
In accordance with the IMI research agenda the DIRECT consortium offers considerable potential to achieve major progress towards a personalized medicines approach for the treatment of type 2 diabetes.